Tag: GlobeNewswire

Nasdaq Copenhagen
Euronext Dublin
London Stock Exchange        
Other stakeholders

Date         2 October 2026
                

New share buyback programme

The bank’s board of directors has decided to launch a new share buyback programme for DKK 400 million as part of the allocation of profit for the 2026 financial year.

The new share buyback programme will be launched when the current DKK 400 million share buyback programme finishes.

The decision on the new share buyback programme conforms to the bank’s distribution policy and was made following approval by the Danish FSA.

Kind regards

Ringkjøbing Landbobank

John Fisker
CEO

Attachment

• New share buyback programme in 2026 3 EN

Bang & Olufsen A/S has, pursuant to the Danish Capital Markets Act, received a major shareholder notification from UBS Group AG.

• As per 28 September 2026, UBS Group AG’s holding of shares and voting rights pursuant to section 38 of the Danish Capital Markets Act, as well as other financial instruments pursuant to section 39(2), was above 5 percent of the total share capital and voting rights in Bang & Olufsen A/S.
• As per 29 September 2026, UBS Group AG’s holding of shares and voting rights pursuant to section 38 of the Danish Capital Markets Act, as well as other financial instruments pursuant to section 39(2), was below 5 percent of the total share capital and voting rights in Bang & Olufsen A/S.

As of 29 September 2026, UBS Group AG held a total of 7,282,954 shares and voting rights in Bang & Olufsen A/S, corresponding to 4.94 percent of the total share capital and voting rights.

Correction to the numbering of the company announcement published on 24 September 2026 – Major Shareholder Announcement: The announcement was incorrectly stated as no. 26.18. The correct announcement number is 26.19″.

For further information, please contact:

Cristina Rønde Hefting
Sr. Director, Head of Strategy & Investor Relations
Phone: +45 4153 7303

Attachment

• BO_2622_Major shareholder announcement_UBS

KALMAR CORPORATION, TRADE PRESS RELEASE, 2 OCTOBER 2026 AT 9:00 (EEST)

Kalmar receives order for first two electric reachstackers from Port of Helsingborg under frame agreement signed in Q2

Kalmar has received an order from the Port of Helsingborg (Helsingborgs Hamn) for two electric reachstackers and MyKalmar INSIGHT with Inspector machine inspection solution. The order was booked in Kalmar’s Q3 2026 order intake with delivery scheduled for the end of Q2, 2027. This marks the first equipment order from the Port of Helsingborg under the six-year frame agreement signed in Q2 2026, covering the potential procurement of up to nine zero-emission machines.

Located on Sweden’s Øresund coast, the Port of Helsingborg is the country’s second-largest container port and an important hub for sea, road and rail transport. In 2024, the port became the first in Sweden to order a Kalmar electric reachstacker. It also operates three Kalmar eco reachstackers.

Christina Argelius, Chief Technical Officer, Port of Helsingborg: “Ordering these first two units under our new framework agreement represents an important step in our transition towards lower-emission terminal operations. We are committed to replacing diesel machines in a structured and long-term way. By continuing to invest in sustainable innovations, we are proud to set a strong industry benchmark.”

Eric Wass, Sales Representative, Kalmar Sweden: “It’s fantastic to take this next step with the Port of Helsingborg. Moving away from diesel gives terminals much more security when fuel costs are unpredictable. It’s a pleasure working with the team at Helsingborg because they are just as dedicated to finding sustainable ways of working as we are.”

Further information for the press:

Aino-Leena Juutinen, Director, Marketing and Communications, Counterbalanced:
aino-leena.juutinen@kalmarglobal.com 
+358 44 535 3030

Eric Wass, Sales Representative, Kalmar Sweden
eric.wass@kalmarglobal.com 
+46 706 720 067

Kalmar (Nasdaq Helsinki: KALMAR) is moving goods in critical supply chains around the world, with the vision to be the forerunner in sustainable material handling equipment and services. The company offers a wide range of industry shaping heavy material handling equipment and services to ports and terminals, distribution centres, manufacturing and heavy logistics. Headquartered in Helsinki, Finland, Kalmar operates globally in over 120 countries and employs approximately 5,300 people. In 2025, the company’s sales totalled approximately EUR 1.7 billion. www.kalmarglobal.com 

Attachments

• Kalmar received an order from the Port of Helsingborg for two electric reachstackers
• Kalmar Electric Reachstacker

BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) — Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company’s Marketing Authorisation Application (MAA) for its investigational gene therapy, rebisufligene etisparvovec, for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A.

EMA validation confirms that the application is sufficiently complete for the Agency to begin its formal scientific review. Validation does not constitute approval of the application, nor does it represent a determination regarding the safety or efficacy of the investigational therapy, nor guarantee that the application will ultimately receive marketing authorisation. “The validation of our application by the EMA marks an important regulatory milestone in the ongoing review process for this investigational therapy,” said Jane Cooper, Senior Vice President and Region Head for Europe, Middle East and Africa at Ultragenyx. “We recognize the significant unmet need within the MPS IIIA community and continue to advance our global regulatory strategy with the European Medicines Agency (EMA). We also plan to expand to other geographies over time.”

MPS IIIA is a rare, progressive inherited disorder associated with severe neurological impairment and significant unmet medical need. Currently, treatment options remain limited for affected children and their families. The investigational gene therapy has also received PRIority MEdicines (PRIME) designation and Orphan Drug Designation from the European Medicines Agency, reflecting rarity and the seriousness of MPS IIIA and the significant unmet medical need experienced by affected patients and their families. These designations are intended to support the development and evaluation of medicines for serious conditions and rare diseases and should not be interpreted as an indication that marketing authorisation will be granted.

As an investigational advanced therapy medicinal product, the application will fall within the scope of the European Union’s Joint Clinical Assessment (JCA) framework introduced under the EU Health Technology Assessment Regulation. The JCA is intended to support a coordinated clinical assessment process across EU Member States and represents a new component of the broader pathway to patient access.

The Company is also continuing discussions with health authorities in multiple regions and has initiated regulatory engagement activities with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the Saudi Food and Drug Authority (SFDA) as part of its broader objective to pursue potential future geographic expansion.

About Sanfilippo Syndrome Type A

Sanfilippo syndrome Type A is an ultra-rare, fatal lysosomal storage disease that primarily affects the brain and is marked by rapid, progressive neurodegeneration beginning in early childhood. Children with Sanfilippo syndrome Type A typically experience progressive global developmental delay, followed by the loss of cognitive, language, and motor function, ultimately leading to early death. Sanfilippo syndrome Type A is estimated to affect approximately 3,000 to 5,000 patients in commercially accessible geographies, with a median life expectancy of 15 years. The disease is caused by a deficiency of the sulfamidase (SGSH) enzyme, which results in the accumulation of heparan sulfate substrate in cells and progressive damage to the central nervous system.

About rebisufligene etisparvovec

Rebisufligene etisparvovec is a single-dose intravenous AAV9 gene therapy designed to deliver a functional copy of the deficient enzyme gene that can express and replace the SGSH enzyme. Ultragenyx received FDA approval for rebisufligene etisparvovec on September 17^th 2026.

About Ultragenyx

Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

Forward-Looking Statements and Ultragenyx’s Use of Digital Media
Except for the historical information contained herein, this press release contains forward-looking statements, including statements regarding the EMA’s review of the Marketing Authorisation Application for rebisufligene etisparvovec (UX111); the potential timing and outcome of that review and any European Commission decision; the potential safety, efficacy and benefits of UX111; the Joint Clinical Assessment process and potential patient access in EU Member States; and Ultragenyx’s plans for regulatory engagement and potential expansion in other geographies. These statements are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, among others, the possibility that the EMA or other health authorities request additional data, studies or manufacturing information, delay review, or decline to grant marketing authorisation or other approvals; that clinical data do not establish the safety and efficacy required for approval; that manufacturing, quality or supply issues arise; that the Joint Clinical Assessment or national pricing and reimbursement processes delay or limit patient access; and that engagement with authorities outside the EU does not result in submissions or approvals. PRIME and orphan designations, and EMA validation of the application, do not assure approval or patient access.

For further information about risks and uncertainties affecting Ultragenyx, see its Quarterly Report on Form 10-Q filed on August 5, 2026, and subsequent periodic reports filed with the SEC. Ultragenyx undertakes no obligation to update or revise these forward-looking statements, except as required by law

In addition to its SEC filings, press releases and public conference calls, Ultragenyx uses its investor relations website and social media outlets to publish important information about the company, including information that may be deemed material to investors, and to comply with its disclosure obligations under Regulation FD. Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyx’s Investor Relations website (https://ir.ultragenyx.com/) and LinkedIn website (https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/).

Contact
media@ultragenyx.com

MRCNP-UX111-00098

                                       FOR IMMEDIATE RELEASE 

Contact:         
Highvern Fund Services Limited 
Company Administrator 
Attn: Nicole Barnes 
Tel: +44 1481 752957

Eurocastle Announces Change in Registered Office

Guernsey, 2 October 2026

Eurocastle Investment Limited announces that with effect from the 1 October 2026, its Registered Office has changed to Ground floor, Mill Court, La Charroterie, St Peter Port, Guernsey, GY1 1EJ.

This is as a result of the change in Registered Office of its Guernsey Administrator, who has also changed its name from Oak Fund Services (Guernsey) Limited to Highvern Fund Services Limited.

ABOUT EUROCASTLE

Eurocastle Investment Limited (“Eurocastle” or the “Company”) is a publicly traded closed-ended investment company. On 8 July 2022, the Company announced the relaunch of its investment activity and is currently in the early stages of pursuing its new strategy by initially focusing on opportunistic real estate in Greece with a plan to expand across Southern Europe. For more information regarding Eurocastle Investment Limited and to be added to our email distribution list, please visit www.eurocastleinv.com.

ICG Enterprise Trust plc (the “Company”)

2 October 2026

Transaction in Own Shares

The Company announces that on 1 October 2026 it bought back 75,000 of its own shares under the opportunistic buyback programme, to be held as treasury shares, at an average price of 1393 pence per share.

Further details are set out below:

• Number of shares held as treasury shares following settlement of this purchase: 3,447,500
• Total shares in issue excluding treasury shares following settlement of this purchase: 60,106,692

The Company has bought back these shares under the authority granted by shareholders at its Annual General Meeting in June 2026, which permits the Company to repurchase a maximum of 14.99% of its ordinary shares. The actual number of shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2027), or until expressly revoked by shareholders.

No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company’s current intention to hold any shares bought back in treasury.

The Company has instructed Numis Securities Limited (trading for these purposes as Deutsche Numis) as its broker in respect of its buyback transactions. This arrangement is in accordance with the UKLA Listing Rules and the Company’s general authority to repurchase shares.

Analyst / Investor enquiries:

Chris Hunt
Shareholder Relations, ICG
+44 (0) 20 3545 2020

Andrew Lewis
Company Secretary, ICG
+44 (0) 20 3545 1344

Media:

Clare Glynn
Corporate Communications, ICG
+44 (0) 20 3545 1395

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Transaction in Own Shares

St Peter Port, Guernsey 2 October 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 11 June 2026 and the share buy-back agreement with Jefferies International Limited.

Transaction on London Stock Exchange

Date of purchase of Shares	1 October 2026
Number of Shares purchased	43,650 Class A Shares
Highest price/lowest price paid	£14.76 / £14.68
ISIN for the Shares	GG00B1ZBD492

All Class A Shares bought back will be cancelled. Following the cancellation, the number of outstanding Class A Shares is 37,527,816‬. The Company also has 3,150,408 Class A shares held in treasury. For reporting purposes under the FCA’s Disclosure Guidance and Transparency Rules the market should use the figure of 37,527,816 voting rights when determining if they are required to notify their interest in, or a change to their interest in the Company.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Oak Group        +44 1481 723450

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

Neuberger Private Equity Partners Limited (“NBPE”) invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger

Neuberger was founded in 1939 to do one thing: deliver compelling investment results for our clients over the long term. This remains our singular purpose today, driven by a culture rooted in deep fundamental research, the pursuit of investment insight and continuous innovation on behalf of clients, and facilitated by the free exchange of ideas across the organization.

From offices in 39 cities[1] across 26 countries, Neuberger manages a range of equity, fixed income, private equity and hedge fund strategies on behalf of institutions, advisors and individual investors worldwide. With more than 780[1] investment professionals and over 2,900[1] employees in total, Neuberger has built a diverse team of individuals united in their commitment to client outcomes and investment excellence. Our culture has afforded us enviable retention rates among our senior investment staff and we are proud to have been ranked 1st by Pensions & Investments in their 2025 “Best Places to Work in Money Management” survey, where we have placed 1st in four of the last five years and finished in the top two for 12 consecutive years[2].

As a private, independent, employee-owned investment manager, Neuberger is structurally aligned with the long-term interests of our clients. We have no external parent or public shareholders to serve, nor other lines of business to distract us from our core mission. And with our employees and their families invested alongside our clients—plus 100% of employee deferred cash compensation directly linked to team and firm strategies—we are truly in this together.
For more information, please visit our website: www.nb.com/en/global/who-we-are.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

[1] Firm data reflects the collective data for the various subsidiaries of Neuberger Berman Group LLC as of 30 June 2026.

[2] Among organizations with over 1,000 employees by Pensions & Investments. For additional information on the criteria for the award, please visit https://www.pionline.com/awards/best-places-to-work-in-money-management/pi-best-places-to-work-2025.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

This press release appears as a matter of record only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.

NBPE is established as a closed-end investment company domiciled in Guernsey. NBPE has received the necessary consent of the Guernsey Financial Services Commission. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. This document is not intended to constitute legal, tax or accounting advice or investment recommendations. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Statements contained in this document that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of NBPE’s investment manager. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this document contains “forward-looking statements.” Actual events or results or the actual performance of NBPE may differ materially from those reflected or contemplated in such targets or forward-looking statements.

Press release

Lochem, 2 October 2026 

ForFarmers and KPS Food Group joint venture in Poland completed

ForFarmers and KPS Food Group have completed the formation of the joint venture ForFarmers Polska, which was announced on 12 February 2026. All conditions for this transaction have been met, including approval from the shareholders and the local competition authority.

With the completion of the transaction, the operations of Tasomix and KPS will be brought together under ForFarmers Polska. ForFarmers holds a majority stake of 50.5 per cent in the joint venture and will consolidate it in full. The founders of Tasomix and KPS will remain minority shareholders in the joint venture.

The partnership strengthens ForFarmers’ position in the growing Polish poultry market and represents an important step in the further integration of the agricultural value chain. The combination of Tasomix’s feed expertise and KPS’s strong position in poultry production, processing and marketing creates a powerful, integrated organisation that is well positioned for further growth.

The transaction completed today relates to the main joint venture, concerning the activities of KPS and Tasomix. In addition, a second, separate, joint venture forms part of the overall agreement. This joint venture focuses on specific sales activities and contracts and is expected to be completed over the coming months.

Capital Market Day
During the Capital Market Day taking place on 24 November 2026, ForFarmers Polska and KPS Food Group will be discussed in more detail. 

This press release contains information that constitutes inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Note to editors / For further information: 
Floor van Maaren, +31 (0)573 28 88 00

Company profile ForFarmers N.V.
ForFarmers N.V. (“ForFarmers”) is a company offering complete feed solutions for conventional and organic livestock farming. Through its mission, “For the Future of Farming”, ForFarmers is committed to building a future-proof farming sector and supporting the further sustainability of agriculture. Our objective is clear: to contribute to profitable farm businesses and a robust long-term earning model. We do this by leading with knowledge, advice, support and products at farm level. Close to farmers, solution-oriented and with an open view of the future. The result is a contribution to affordable and sustainable food production, For the Future of Farming.
With annual feed volumes of approximately 9 million tonnes, ForFarmers is a leading player in Europe. The company has production operations in the Netherlands (head office), Germany, Poland and the United Kingdom, and exports to various countries within and outside Europe. ForFarmers employs approximately 2,700 people. ForFarmers N.V. is listed on Euronext Amsterdam.
ForFarmers N.V.
P.O. Box 91, 7240 AB Lochem, the Netherlands
T: +31 (0)573 28 88 00
E: info@forfarmers.eu
W: www.forfarmersgroup.eu

FORWARD-LOOKING STATEMENTS
This document contains forward-looking statements that include ForFarmers’ regulatory capital and liquidity positions under certain specified scenarios. In addition, forward-looking statements may include, without limitation, statements containing words such as ”intends”, ”expects”, ”takes into account”, ”aims at”, ”has the plan”, ”estimates” and words of similar purport. These statements concern or may affect future matters, such as ForFarmers’ future financial results, business plans and current strategies. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results and performance to differ materially from the expected future results or performance implicitly or explicitly contained in forward-looking statements. Factors that may cause, or contribute to, differences in current expectations include, but are not limited to: developments in legislation, technology, taxation, case law and regulations, fluctuations in stock prices, legal proceedings, investigations by regulators, competitive conditions, and general economic conditions. These and other factors, risks and uncertainties that may affect any forward-looking statement or the actual results of ForFarmers are discussed in the latest published annual report. The forward-looking statements contained in this document relate solely to statements as of the date of this document, and ForFarmers assumes no obligation or responsibility to update the forward-looking statements contained in this announcement, whether in connection with new information, future events or otherwise, unless ForFarmers is required by law to do so.

• Jean-Philippe Rocher Appointed Head of Pharmaceutical Development
• Mikhail Kalinichev, Head of Translational Science, Steps Down

Ad Hoc Announcement Pursuant to Art. 53 LR

Geneva, Switzerland, October 2, 2026 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment of Jean-Philippe Rocher as Head of Pharmaceutical Development and member of the Executive Management. Dr. Rocher has more than 30 years of experience in drug discovery and development within the pharmaceutical and biotech industry, including previous roles at Addex. Mikhail (“Misha”) Kalinichev has decided to step down from his role as Head of Translational Science at Addex to focus on a similar position he holds at Neurosterix.

“I’d like to welcome Jean-Philippe back to Addex following his retirement from Neurosterix. He is a pioneer in allosteric modulation approaches and was instrumental in industrializing our chemistry platform to deliver small molecule allosteric modulator clinical candidates at Addex and Neurosterix. His expertise will help guide the next phase in our clinical development plan,” said Tim Dyer, CEO of Addex. “I’d also like to thank Misha for his dedication and contribution to our pipeline development and the founding of our spin out company Neurosterix. We all wish him well as he focuses solely on his role at Neurosterix.”

“I’m rejoining Addex at a pivotal time for the company following regaining rights to our GABAB PAM program from Indivior. With several drug candidates ready to start clinical development, I am looking forward to helping Tim and the team on progressing the Addex pipeline to the next stage,” said Dr. Rocher.

Dr. Rocher returns to Addex after retiring from his role as Head of Pharmaceutical Development at Neurosterix, which started in 2024 following the spin-out from Addex. He first rejoined Addex in 2018 from his position as CNS Program Director at Pierre Fabre. Joining Addex at its inception in 2002, Dr. Rocher established the company’s chemistry capabilities and helped build its small molecule allosteric modulator chemistry platform and pipeline. He played a pivotal role in the success of both internal and partnered programs, including the discovery of dipraglurant and ADX71149, both of which progressed into phase II clinical development. Under the leadership of Dr Rocher, Addex team discovered ADX71441, which was recently licensed to Indivior PLC. Prior to joining Addex, Dr. Rocher was director of chemistry at Devgen NV (Gent, Belgium), senior research scientist for GlaxoSmithKline KK (Tsukuba, Japan), scientific project leader in CNS at Mitsubishi Tanabe (Yokohama, Japan) and Head of Drug Discovery Unit for Battelle (Geneva, Switzerland). He started his career as a research scientist in the dermatology research centre of Galderma (Sophia-Antipolis, France) following a PhD in medicinal chemistry and Pharm D at the Faculty of Pharmacy of Lyon (France).He is a co-author of more than 50 research publications and patents.

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is a Phase 2 ready asset under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex is developing a GABAB PAM drug candidate for substance use disorders that has successfully completed IND enabling studies and a second GABAB PAM program for chronic cough, which is ready to start IND enabling studies. Addex holds a 20% equity interest in a private spin-out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders, and a mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.                                       

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com.
  
Contacts: 

Tim Dyer  Chief Executive Officer  Telephone: +41 22 884 15 55  PR@addextherapeutics.com

Mike Sinclair  Partner, Halsin Partners  +44 (0)7968 022075  msinclair@halsin.com

Addex Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Corbion today announces that CEO Olivier Rigaud has informed the Supervisory Board that he will not seek a third term as CEO when his current appointment expires at the Annual General Meeting of Shareholders (AGM) on 12 May 2027.

After eight years as CEO, Olivier believes the end of his current term will be the right moment to hand over leadership of the company. During his tenure, he has guided Corbion through a period of significant transformation and strengthened the company’s position for future growth and value creation. Olivier will remain fully committed to Corbion and continue to lead the company until the AGM on 12 May 2027, with a continued focus on improving performance, strengthening execution and advancing the company’s strategic priorities.

The Supervisory Board has initiated a succession process to identify Corbion’s next CEO. The Supervisory Board is confident that the planned transition timeline provides ample opportunity to ensure continuity of leadership, a smooth handover, and continued focus on delivering long term value for customers, employees, shareholders and other stakeholders.

In addition, the Supervisory Board intends to nominate Alexander (Xander) Wessels for appointment as a member of the Supervisory Board at an Extraordinary General Meeting.

Xander Wessels, a Dutch national, brings extensive experience in the life sciences, specialty chemicals and food ingredients industries, with deep expertise in strategy, operational excellence, international business leadership and value creation. Throughout his career, he has held a number of senior leadership positions, including Chief Executive Officer of Caldic, Chief Executive Officer of Archroma, and President and Chief Executive Officer of DSM Pharmaceutical Products. Earlier in his career, he also held senior leadership roles within DSM and Campina. Currently, he serves as Chair of the Supervisory Board of NRG PALLAS and Chair of Enza Zaden, and is a member of the Board of Directors of Archroma.

The Supervisory Board believes that Mr. Wessels’ experience in leading international B2B companies, driving transformation and operational performance, and serving on supervisory boards will be highly valuable as Corbion continues to execute BRIGHT 2030, strengthen performance and create long-term value for stakeholders.

Attachment

• 2026-02-10_Corbion_PR_CEO_SB